```html

Qat (Khat)‑Induced Psychosis – A Comprehensive Medical Guide

Overview

Qat (also spelled khat, scientific name Catha edulis) is a leafy stimulant native to the Horn of Africa and the Arabian Peninsula. When chewed or brewed into a tea, the leaves release psycho‑active alkaloids – mainly cathinone and cathine – that produce euphoria, increased alertness, and appetite suppression. While many users experience only mild, short‑lasting effects, heavy or chronic use can precipitate a severe mental health condition known as **Qat‑induced psychosis**.

• Who it affects: Primarily adult males aged 18‑45 in regions where Qat is culturally accepted (Yemen, Somalia, Ethiopia, Djibouti, Kenya, and parts of the Arabian Gulf). However, women, adolescents, and immigrants in Western countries who use Qat recreationally can also develop psychosis.
• Prevalence: Epidemiological data are limited because Qat is illegal in many countries, but studies from Yemen estimate that up to 4–7 % of regular chewers develop psychotic symptoms, with an incidence of roughly 0.5–1 case per 1,000 person‑years among heavy users (Al‑Khaldi et al., 2020; WHO, 2022).
• Why it matters: Psychosis can impair judgment, increase the risk of violent behavior, and lead to long‑term psychiatric illness if not recognized early.

Symptoms

Psychotic features triggered by Qat typically emerge after days to weeks of high‑dose, continuous chewing (often >4 g of fresh leaves per day) or after a binge in previously tolerant users. Symptoms can be transient (lasting <48 h) or persist for weeks, resembling primary schizophrenia.

Positive Symptoms (excesses)

• Hallucinations: Auditory (hearing voices), visual (seeing shapes or people), or tactile (feeling bugs crawling).
• Delusions: Fixed false beliefs such as persecution (“they are watching me”), grandiosity (“I have special powers”), or somatic ideas (“my body is poisoned”).
• Disorganized speech: Loose associations, neologisms, or rapid, pressured talking.
• Paranoid thinking: Heightened suspicion of friends, family, or authorities.

Negative Symptoms (deficits)

• Emotional flattening or reduced affect.
• Social withdrawal and lack of motivation (avolition).
• Reduced speech output (poverty of speech).

Other Neuropsychiatric Features

• Insomnia & severe agitation – often the first clue that Qat use is exceeding a tolerable threshold.
• Manic‑like symptoms: Euphoria, racing thoughts, grandiosity, and increased goal‑directed activity.
• Anxiety, panic attacks, or dysphoric mood when the stimulant wears off.
• Cognitive impairment: Poor concentration, memory lapses, and slowed processing.

Causes and Risk Factors

Qat‑induced psychosis is a substance‑induced psychotic disorder. The primary pathogenic mechanisms involve the amphetamine‑like actions of cathinone, which increase synaptic dopamine, norepinephrine, and serotonin.

Primary Causes

• Cathinone excess: High concentrations (>5 % by weight in fresh leaves) boost dopaminergic transmission in the mesolimbic pathway, a neuro‑circuit commonly implicated in psychosis.
• Polysubstance use: Concurrent alcohol, cannabis, or prescription stimulant use compounds the risk.
• Withdrawal: abrupt cessation after heavy use can unmask psychotic symptoms.

Risk Factors

• Frequency & dosage: Chewing >3 hours daily for >6 months dramatically raises risk.
• Genetic predisposition: Family history of schizophrenia, bipolar disorder, or other psychotic illnesses.
• Pre‑existing mental health conditions: Mood disorders, anxiety, or prior substance‑induced psychosis.
• Young age of onset: Regular use before age 20 is linked with a higher conversion rate to chronic psychosis.
• Social stressors: Unemployment, displacement, or trauma can interact with Qat’s stimulant effects.
• Medical comorbidities: Hepatic or renal impairment reduces cathinone clearance, increasing plasma levels.

Diagnosis

Diagnosis follows the criteria for Substance‑Induced Psychotic Disorder as outlined in the DSM‑5‑TR and ICD‑11. Clinicians must demonstrate that psychotic symptoms are temporally linked to Qat use, that they are not better explained by another psychiatric condition, and that they cause clinically significant distress or impairment.

Diagnostic Steps

1. Comprehensive history: Detailed Qat consumption pattern (amount, frequency, route), other substance use, psychiatric and family history.
2. Physical & neurological exam: Look for signs of stimulant toxicity (tachycardia, hypertension, tremor) and rule out organic causes.
3. Laboratory testing:
   • Urine toxicology for cathinone, amphetamines, cannabis, and alcohol.
   • Basic metabolic panel, liver function tests, and renal panel to assess organ function.
   • Thyroid function tests – hyperthyroidism can mimic psychosis.
4. Imaging (if indicated): MRI or CT head to exclude intracranial pathology when focal deficits or atypical features are present.
5. Psychiatric assessment tools: Brief Psychiatric Rating Scale (BPRS) or Positive and Negative Syndrome Scale (PANSS) to quantify severity.

Key Diagnostic Criteria (DSM‑5‑TR)

• Presence of delusions or hallucinations.
• Evidence that the symptoms developed during or within a month of Qat use.
• Disturbance is not better accounted for by a primary psychotic disorder or another medical condition.
• If the psychosis persists >1 month after cessation, a diagnosis of primary schizophrenia should be reconsidered.

Treatment Options

Treatment is a blend of acute pharmacologic management, safe detoxification, and long‑term psychosocial support.

Acute Phase (first 24‑72 hours)

• Antipsychotics:
  • First‑generation: Haloperidol 5‑10 mg IM/IV for rapid calming.
  • Second‑generation: Risperidone 2‑4 mg PO or Olanzapine 5‑10 mg PO – preferred for lower risk of extrapyramidal symptoms.
• Benzodiazepines: Lorazepam 1‑2 mg IV/PO every 4‑6 h for agitation or severe insomnia.
• Supportive care: IV fluids, electrolytes, and monitoring of vitals; treat hypertension or tachyarrhythmia as needed.

Detoxification & Stabilization (1‑2 weeks)

• Gradual taper: If the patient has been using high‑dose Qat daily, a slow reduction (e.g., 10 % less each day) minimizes withdrawal‑induced relapse.
• Adjunctive meds:
  • Antidepressants (e.g., Sertraline 50 mg) if depressive symptoms coexist.
  • Mood stabilizers (e.g., Lithium 300 mg BID) for mixed manic‑psychotic presentations.

Long‑Term Management

1. Maintenance antipsychotics: Continue low‑dose second‑generation agents for 6–12 months; taper only after sustained remission and abstinence.
2. Psychotherapy: Cognitive‑behavioral therapy for psychosis (CBTp) helps patients challenge delusional thoughts and develop coping strategies.
3. Substance‑use counseling: Motivational interviewing and relapse‑prevention groups (e.g., SMART Recovery) specifically targeting Qat.
4. Community resources: Integration with local cultural leaders and religious figures can improve adherence in regions where Qat is socially embedded.

When Pharmacologic Treatment May Not Be Needed

If psychotic symptoms resolve completely within 48 hours of Qat cessation and no other risk factors exist, close outpatient monitoring (weekly visits) may suffice without antipsychotics.

Living with Qat (Khat)‑Induced Psychosis

Even after symptom remission, patients often face daily challenges related to cravings, stigma, and the social context of Qat chewing.

• Set a quit date: Write down a specific day and share it with a trusted friend or counselor.
• Identify triggers: Social gatherings where Qat is offered, stress at work, or nighttime boredom. Develop alternative activities (exercise, reading, hobby clubs).
• Build a support network: Join a peer‑support group, engage family in therapy, and consider a “buddy system” for high‑risk moments.
• Maintain a healthy routine: Regular sleep (7‑9 h), balanced meals, and moderate physical activity reduce dopamine spikes.
• Medication adherence: Use pillboxes, alarms, or smartphone reminders; never stop antipsychotics abruptly without physician guidance.
• Monitor mental status: Keep a daily log of mood, sleep, and any subtle psychotic symptoms; report changes promptly.
• Legal & occupational considerations: In countries where Qat is illegal, disclose use to occupational health services if required; seek legal counseling if facing charges.

Prevention

Preventing Qat‑induced psychosis hinges on reducing exposure and building resilience.

1. Public education: Community campaigns highlighting the psychiatric risks of chronic Qat use – especially targeted at youths and male laborers.
2. Regulation: Enforcement of existing bans in nations where Qat is illegal; licensing and taxation where it is legal to limit bulk sales.
3. Screening in primary care: Routine questioning about Qat use in at‑risk populations (e.g., immigrants from the Horn of Africa).
4. Early intervention programs: Offer brief counseling after the first episode of heavy use or mild psychotic symptoms.
5. Alternative social rituals: Promote non‑stimulant cultural practices (e.g., tea ceremonies, sports) to replace Qat‑centric gatherings.

Complications

If left untreated, Qat‑induced psychosis can lead to severe short‑ and long‑term consequences.

• Progression to chronic psychotic disorder: Up to 30 % of individuals with an initial substance‑induced episode develop schizophrenia‑like illness within 5 years (Mayo Clinic, 2021).
• Self‑harm or aggression: Hallucinations or delusional paranoia can precipitate suicide attempts or violent outbursts.
• Cardiovascular complications: Persistent hypertension, arrhythmias, and increased risk of myocardial infarction from chronic catecholamine surge.
• Neurocognitive decline: Prolonged cathinone exposure has been associated with deficits in working memory and executive function.
• Social and occupational loss: Relationship breakdown, job loss, legal problems, and homelessness.
• Polysubstance dependence: Users may shift to other stimulants (e.g., amphetamines) when Qat becomes unavailable.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Substance‑Induced Psychotic Disorder.” 2021; World Health Organization. “Khat (Catha edulis) – Health Impacts.” 2022; Al‑Khaldi et al., *Journal of Psychoactive Substances*, 2020; CDC. “Drug Use and Mental Health.” 2023; National Institute on Drug Abuse (NIDA). “Stimulant‑Related Disorders.” 2022; Cleveland Clinic. “Managing Cannabis‑Induced Psychosis.” 2024.

```